

## CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
10 May 2001 (10.05.2001)

PCT

(10) International Publication Number  
WO 01/32627 A1(51) International Patent Classification<sup>7</sup>: C07D 231/12, 231/22, 231/26, 231/38, 401/04

(74) Agents: RAYMOND, Robert, P. et al.: Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US).

(21) International Application Number: PCT/US00/29891

(81) Designated States (national): AE, AU, BG, BR, CA, CN, CZ, EE, HR, HU, ID, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, UA, UZ, VN, YU, ZA.

(22) International Filing Date: 27 October 2000 (27.10.2000)

(84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(25) Filing Language: English

## Published:

— with international search report

(26) Publication Language: English

(48) Date of publication of this corrected version:

24 January 2002


(71) Applicant: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. [US/US]; 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US).

(15) Information about Correction:  
see PCT Gazette No. 04/2002 of 24 January 2002, Section II

(72) Inventors: BARON, James, A.; 3472 Darby Glen Road, Hilliard, OH 43026 (US). FARINA, Vittorio; 127 Skunk Lane, Wilton, CT 06897 (US). HADDAD, Nizar; 30 Pondcrest Road, Danbury, CT 06811 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS OF MAKING SUBSTITUTED PYRAZOLES



WO 01/32627 A1

(57) Abstract: Disclosed is a process of making substituted pyrazoles (I) from substituted benzophenone hydrazones (II) with a variety of 1,3-bifunctional substrates (III) under acid conditions. The pyrazole compounds are useful for making pharmaceutical compounds. In said formula, wherein X is chosen from -CN and -C(O)-R<sub>3</sub> wherein if X is CN then R<sub>3</sub> in the product formula (I) is amino.